GAMMA Investing LLC Raises Stock Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM)

GAMMA Investing LLC raised its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 549.9% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 37,185 shares of the company's stock after purchasing an additional 31,463 shares during the quarter. GAMMA Investing LLC's holdings in Beam Therapeutics were worth $726,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Wealthfront Advisers LLC bought a new stake in shares of Beam Therapeutics during the 4th quarter valued at about $41,000. GF Fund Management CO. LTD. bought a new stake in shares of Beam Therapeutics during the 4th quarter valued at about $43,000. Sterling Capital Management LLC grew its stake in shares of Beam Therapeutics by 816.0% during the 4th quarter. Sterling Capital Management LLC now owns 2,409 shares of the company's stock valued at $60,000 after purchasing an additional 2,146 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Beam Therapeutics during the 4th quarter valued at approximately $191,000. Finally, Summit Investment Advisors Inc. grew its stake in shares of Beam Therapeutics by 6.6% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,999 shares of the company's stock valued at $198,000 after acquiring an additional 496 shares during the period. 99.68% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

BEAM has been the subject of a number of recent research reports. Royal Bank Of Canada boosted their price objective on Beam Therapeutics from $24.00 to $26.00 and gave the company a "sector perform" rating in a research note on Wednesday, February 26th. Wedbush reissued an "outperform" rating and issued a $57.00 price target on shares of Beam Therapeutics in a report on Monday, March 10th. Barclays lowered their price target on Beam Therapeutics from $31.00 to $25.00 and set an "equal weight" rating on the stock in a report on Wednesday, May 7th. Cantor Fitzgerald reissued an "overweight" rating on shares of Beam Therapeutics in a report on Wednesday, March 12th. Finally, Wells Fargo & Company lowered their price target on Beam Therapeutics from $75.00 to $70.00 and set an "overweight" rating on the stock in a report on Wednesday, May 7th. Two investment analysts have rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Beam Therapeutics has an average rating of "Buy" and a consensus price target of $48.75.

Beam Therapeutics Price Performance

Shares of BEAM opened at $16.67 on Wednesday. The stock has a market capitalization of $1.68 billion, a price-to-earnings ratio of -3.62 and a beta of 2.08. Beam Therapeutics Inc. has a 1 year low of $13.53 and a 1 year high of $35.25. The business's 50 day simple moving average is $17.61 and its 200-day simple moving average is $22.88.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($1.24) earnings per share for the quarter, missing the consensus estimate of ($1.11) by ($0.13). Beam Therapeutics had a negative net margin of 609.24% and a negative return on equity of 44.24%. The company had revenue of $7.47 million for the quarter, compared to analysts' expectations of $14.69 million. During the same quarter in the previous year, the company posted ($1.21) EPS. The business's quarterly revenue was up 1.4% on a year-over-year basis. On average, sell-side analysts expect that Beam Therapeutics Inc. will post -4.57 earnings per share for the current year.

Insider Activity at Beam Therapeutics

In other Beam Therapeutics news, insider Christine Bellon sold 5,674 shares of the company's stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $18.35, for a total value of $104,117.90. Following the transaction, the insider now owns 117,294 shares of the company's stock, valued at $2,152,344.90. This represents a 4.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO John M. Evans sold 30,663 shares of the company's stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $18.35, for a total value of $562,666.05. Following the completion of the transaction, the chief executive officer now directly owns 986,249 shares in the company, valued at $18,097,669.15. This trade represents a 3.02% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 43,771 shares of company stock worth $803,198. Company insiders own 3.50% of the company's stock.

Beam Therapeutics Profile

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.